Endogenous risk factors in Parkinson's disease: Dopamine and tetrahydroisoquinolines

Polish Journal of Pharmacology

Volumn 54, Issue 6, 2002, Pages 567-572

  Antkiewicz Michaluk, Lucyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Dopamine and apoptosis; Endogenous nuerotoxins; MPTP; Neuroprotection; Parkinson's disease; Tetrahydroisoquinoline derivatives

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMANTADINE; ANTIOXIDANT; APOMORPHINE; APOPTOSIS INHIBITOR; ASCORBIC ACID; BETA CAROTENE; BROMOCRIPTINE; BUDIPINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTATHIONE; LISURIDE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PRAMIPEXOLE; SALSOLINOL; SCAVENGER; SELEGILINE; TETRAHYDROISOQUINOLINE DERIVATIVE; UBIQUINONE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; HUMAN; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; REGULATORY MECHANISM; REVIEW; RISK FACTOR; STRIATONIGRAL DEGENERATION;

ANIMALS; APOPTOSIS; DOPAMINE; HUMANS; ISOQUINOLINES; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RISK FACTORS;

EID: 0036965466     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E.C., Agid Y.: Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol., 1997, 12, 25-31.
2. Antkiewicz-Michaluk L., Krygowska-Wajs A., Michaluk J., Romańska I., Szczudlik A., Vetulani J.: Plasticity of extrapyramidal dopamine system in Parkinson's disease - a postmortem study. Neurosci. Res. Commun. 1999, 25, 97-109.
3. Antkiewicz-Michaluk L., Krygowska-Wajs A., Szczudlik A., Romańska I., Vetulani J.: Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology. Biol. Psychiat., 1997, 42, 514-518.
4. Antkiewicz-Michaluk L., Michaluk J., Mokrosz M., Romańska I., Lorenc-Koci E., Ohta S., Vetulani J.: Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties. J. Neurochem., 2001, 78, 100-108.
5. Antkiewicz-Michaluk L., Romańska I., Papla I., Michaluk J., Bakalarz M., Vetulani J., Krygowska-Wajs A., Szczudlik A.: Neurochemical changes induced by acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline and salsolinol in dopaminergic structures. Neuroscience, 2000, 96, 59-64.
6. Ben-Shachar D., Eshel G., Finberg J.P.M., Youdim M.B.: The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem., 1991, 56, 1441-1444.
7. Ben-Shachar D., Riederer P., Youdim M.B.: Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem., 1991, 57, 1609-1614.
8. Bertrand E., Lechowicz W., Szpak G.M., Dymecki J.: Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. Folia Neuropathol., 1997, 35, 80-86.
9. Cohen G.: The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J. Neural Transm., 1983, 19, Suppl., 89-103.
10. Dipasquale B., Marini A.M., Youle R.J.: Apoptosis and DNA degradation induced by 1-methyl-phenylpyridinium in neurons. Biochem. Biophys. Res. Commun., 1991, 181, 1442-1448.
11. Ehringer H., Hornykiewicz O.: Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wschr., 1960, 38, 1236-1239
12. Gerlach M., Riederer P., Przuntek H., Youdim M.B.H.: MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. Mol. Pharm., 1991, 208, 273-286.
13. Hirsch E.C., Hunot S., Faucheux. B., Agid Y., Mizuno Y., Mochizuki H., Tatton W.G., Tatton N., Olanow W.C.: Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov. Disord., 1999, 14, 383-385.
14. Langston J.W., Ballard P., Tetrud J.W., Irwin I.: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 1983, 219, 979-980.
15. Maruyama W., Dostert P., Matsubara K., Naoi M.: N-methylsalsolinol produces hydroxyl radicals: involvement to neurotoxicity. Free Radical. Biol. Med., 1995, 19, 67-75.
16. Morikawa N., Naoi M., Maruyama W., Ohta S., Kotake Y., Kawai H., Niwa T., Dostert P., Mizuno Y.: Effects of various tetrahydroisoquinoline derivatives on mitochondrial respiration and the electron transfer complexes. J. Neural Transm., 1998, 105, 677-688.
17. Nagatsu T.: Isoquinoline neurotoxins in the brain and Parkinson's disease. Neuroscience Res., 1997, 29, 99-111.
18. Schapira A.H., Mann V.M., Cooper J.M., Drexter D., Daniel S.E., Jenner P., Clark J.B., Marsden C.D.: Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem., 1990, 55, 2142-2145.
19. Tasaki Y., Makino Y., Ohta S., Hirobe M.: Biosynthesis of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), a possible antiparkinsonian agent. Adv. Neurol., 1993, 60, 231-233.
20. Yamakawa T., Kotake Y., Fujitani M., Shintani H., Makino Y., Ohta S.: Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain. Neurosci. Lett., 1999, 276, 68-70.